Key result
Bupivacaine was approximately 4.5-fold more potent than ropivacaine in open-channel block of human cardiac SCN5A channels (IC50 69.5 μM vs 322.2 μM).
Why the study?
Does bupivacaine differ from ropivacaine in its interaction with human cardiac SCN5A channels?
Does bupivacaine differ from ropivacaine in its interaction with human cardiac SCN5A channels?
Absolute Event Rate: 69.5% vs 322.2%
Modest differences in clinical cardiotoxicity between bupivacaine and ropivacaine are supported by subtle differences in their interaction with human cardiac Na(+) channels, notably a faster recovery from block with ropivacaine.
No takes yet. Share an insight, caveat, or question.
May explain modest cardiotoxicity differences; leaves open clinical translation of SCN5A findings.
Schwoerer et al. (2015) studied this question. Bupivacaine vs. Ropivacaine was evaluated on Open-channel block of SCN5A channels (IC50 in μM). Bupivacaine was approximately 4.5-fold more potent than ropivacaine in open-channel block of human cardiac SCN5A channels (IC50 69.5 μM vs 322.2 μM).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: